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Ischemia reperfusion injury (IRI) is related to different surgical interventions such
as organ resection and transplantation, and therefore its prevention is of great interest.
However, several decades of investigations have not, unfortunately, lead to a definitive
solution for the treatment of IRI due to its complex and multifactorial pathophysiology with
a plethora of underlying mechanisms that are shared among different organs (heart, brain,
liver, kidney, etc.) [1–3]. The deep exploration of specific IRI pathophysiological and
molecular mechanisms is needed to define strategies to reduce its deleterious effects.
IRI is the most important cause of graft failure in transplantation besides immuno-
logical rejection. This is the result of cumulative damage that depends on the strength,
duration and intensity of the different episodes inherent to transplantation, and leads to
the appearance of organ primary/secondary failure, which may happen as a consequence
of a re-transplantation [4,5].
Along this Special Issue “Molecular Mechanisms and Pathophysiology of Ischemia-
Reperfusion Injury 2.0” we provide a broad overview of the recent insights on several
strategies adopted influencing different molecular and pathophysiological mechanisms
involved in different organs such as heart, brain, liver and kidney. These strategies in
clinical surgery and transplantation embrace the current understanding of some of the
underlying pathophysiological molecular pathways and in turn better knowledge of them
is determinant to counteract the IRI deleterious effects. Here, we report new advances in
IRI molecular mechanisms associated with different strategies, such as ischemic precondi-
tioning (IP) and post-conditioning (Post C) [6–8], which are used to reduce the deleterious
effects of IRI; including other new approaches based on using micro RNAs (miRNAs) [9–11]
or mesenchymal cells [12].
It is well-known that the activation of molecular sensors, such as nitric oxide and
AMPK, are tied to IP and PostC [13–15]. On this line, recent investigations have produced
evidence that the action on the melatonin receptor agonists on melatonin 1 (MT1) and 2
(MT2) receptors induced by Ramelteon is an effective heart preconditioning tool against
IRI [16]. In addition, recent PostC investigations have shown that AMPK activation is
associated with increased glucose metabolism activity in a model of isolated heart after
circulatory death [17]. Alternatively, the use of mi-RNAs has been shown to be efficient in
countering the deleterious effects of IRI [9–11], although it may interfere with the induction
of other specific mi-RNAs when pathological conditions such as hypercholesterinemia are
present in preconditioned hearts [18].
Moreover, there is growing evidence in the brain that factors such as CELSR1 (Cad-
herin epidermal growth factor (EGF) laminin G (LAG) seven-pass G-type receptor) are
responsible for neuroprotective effects on cerebral ischemia injury [19]. This is consistent
with the recent investigations of Schuhmann, M.K. et al. [20] demonstrating that targeting
platelet GPVI plus rt-PA administration but not α2β1-Mediated Collagen Binding also
limits the deleterious effects of ischemia in mice brain injury.
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Recent efforts have been conducted to avoid the detrimental injury effects that occur
during liver resection interventions by inhibiting iNOS with L-NAME [21], as well as those
associated with the rewarming injury after cold graft preservation, which are relevant in
the context of transplantation [22]. With this in mind, several machine perfusion (MP)
strategies [23–25] have been introduced to better preserve the graft before the subsequent
liver transplantation. In general terms, the main goal is to provide vascular flow and
oxygen to the donor graft during preservation; either in hypothermic oxygenated perfusion
(HOPE) [23,24] (using a perfusion solution, normally Belzer-MPS) or in normothermic
MP perfusion (NMP) [25] (using blood or other fluids with oxygen carrying capacity).
These strategies can be applied either immediately after organ procurement or after static
cold storage (SCS). In any case, the oxygenation of the organs is an unsolved problem that
attracts the interest and efforts of researchers in the field [26,27].
Several MP investigations in kidney have shown the benefits of incorporating an-
tioxidants, such as Vectisol, which decreases the early levels of the detrimental radical
oxygen species (ROS) [28] or mesenchymal cells, opening a new window to administer
cell therapy to damaged organs [29] through MP in different preclinical transplantation
models. These promising MP perspectives in kidney [28–30] have been extended to liver
by using HOPE to rescue vulnerable livers, such as the ones from donors after cardiac
death (DCD) and steatotic ones [24,25]. In this sense, the recent investigations by Schlegel
et al. [23] have established the protection mechanisms of HOPE based on the metabolism
of succinate. However, the establishment of new markers to evaluate the quality of the
liver grafts is a pending challenge for the immediate future in IRI investigations [31–33].
Recently, a new perfusate named IGL2 containing PEG35 as oncotic agent [34] has been
proposed for HOPE. IGL2 benefits are associated with a better preservation of the mitochon-
dria integrity, thus assuring the most suitable restoration of the mitochondrial function and
avoiding the inherent redox stress, as suggested by Hofmann et al. [35]. In addition, PEG35
would facilitate the mechano-transduction processes due to its fluid dynamic properties in
HOPE [36]. Finally, it is important to consider the potential use of PEG35 as an additive
to the perfusates used in NMP, such as blood and solutions containing oxygen carriers.
This would be consistent with the benefits of i.v. PEG35 administration in rats subjected
to warm ischemia reperfusion [37] where the deleterious effects of IRI were prevented.
Further investigations are needed.
In conclusion, the challenge for the upcoming years is to explore in depth the complex
molecular pathophysiological mechanisms inherent to IRI in order to establish new frontiers
for future interventions in clinical transplantation.
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